John Paul Waymack
Directeur Technique/Scientifique/R&D chez MOLECULIN BIOTECH, INC.
Postes actifs de John Paul Waymack
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MOLECULIN BIOTECH, INC. | Directeur Technique/Scientifique/R&D | - | - |
Pam-Bio Ltd.
 Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | Directeur/Membre du Conseil | - | - |
Historique de carrière de John Paul Waymack
Anciens postes connus de John Paul Waymack
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PURPLE BIOTECH LTD | Président | 12/08/1968 | 01/07/2019 |
| Directeur Technique/Scientifique/R&D | 12/08/1968 | 09/01/2020 | |
| Fondateur | 12/08/1968 | 09/01/2020 | |
| University of Medicine & Dentistry of New Jersey | Corporate Officer/Principal | - | - |
| The United States Army Medical Service Corps | Corporate Officer/Principal | - | - |
Kitov Pharmaceuticals Ltd.
 Kitov Pharmaceuticals Ltd. Medical DistributorsDistribution Services Part of Purple Biotech Ltd., Kitov Pharmaceuticals Ltd. is committed to providing cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance. The Israeli company's proposed drug, CM24, attenuates/block tumor growth and metastatic processes, while their novel small molecule, NT219, targets both IRS1/2 and STAT3. CM24 is a monoclonal antibody blocking CEACAM1, and NT219 targets the novel cancer drug resistance pathways. Kitov Pharmaceuticals was acquired by Mainrom Line Logistics Ltd. on July 18, 2013. | Président | - | - |
| Directeur Technique/Scientifique/R&D | - | - | |
| The University of Texas at Austin | Corporate Officer/Principal | - | - |
Statistiques
Internationale
| Etats-Unis | 5 |
| Israël | 4 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 3 |
| Chairman | 2 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
| Distribution Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PURPLE BIOTECH LTD | Health Technology |
| MOLECULIN BIOTECH, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Pam-Bio Ltd.
Pam-Bio Ltd. Pharmaceuticals: MajorHealth Technology Pam-Bio Ltd. develops drug therapy for acute bleeding conditions. The company was founded by Abd Al-Roof Higazi and Nuha Higazi on April 27, 2014 and is headquartered in Nazareth, Israel. | Health Technology |
Kitov Pharmaceuticals Ltd.
Kitov Pharmaceuticals Ltd. Medical DistributorsDistribution Services Part of Purple Biotech Ltd., Kitov Pharmaceuticals Ltd. is committed to providing cancer patients with first-in-class, effective, and durable therapies by overcoming tumor immune evasion and drug resistance. The Israeli company's proposed drug, CM24, attenuates/block tumor growth and metastatic processes, while their novel small molecule, NT219, targets both IRS1/2 and STAT3. CM24 is a monoclonal antibody blocking CEACAM1, and NT219 targets the novel cancer drug resistance pathways. Kitov Pharmaceuticals was acquired by Mainrom Line Logistics Ltd. on July 18, 2013. | Distribution Services |
| The United States Army Medical Service Corps |
- Bourse
- Insiders
- John Paul Waymack
- Expérience